New booster shot aims to strengthen HIV defenses in prior vaccine recipients

NCT ID NCT06665646

First seen Sep 30, 2025 · Last updated May 05, 2026 · Updated 24 times

Summary

This early-stage study tests a new HIV vaccine booster called VRIPRO in 40 healthy adults aged 18–60 who previously received an HIV vaccine in the HVTN 706 trial. Participants will get three shots over 24 weeks. The main goals are to check safety and measure the immune response, especially antibodies against HIV.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bridge HIV CRS

    RECRUITING

    San Francisco, California, 94102, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

    RECRUITING

    Boston, Massachusetts, 02115-6110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Columbia P&S CRS

    WITHDRAWN

    New York, New York, 10032, United States

  • Penn Prevention CRS (Site ID# 30310)

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Seattle Vaccine and Prevention CRS

    WITHDRAWN

    Seattle, Washington, 98104, United States

  • The Hope Clinic of the Emory Vaccine Center CRS

    WITHDRAWN

    Decatur, Georgia, 30030, United States

  • Vanderbilt Vaccine (VV) CRS

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.